Abstract
Accumulating evidence infers the utility of DNA-based urine biomarkers for initial detection of bladder cancer (BC) and surveillance of non-muscle-invasive BC. We have previously described gene panels with utility for these indications, identifying UBC-associated mutations in 96% of all BCs such that the associated urine test is not reliant upon the initial identification of mutations in primary tumour tissue.
Highlights
Accumulating evidence implies the utility of DNA-based urine biomarkers for initial detection of bladder cancer (BC) and surveillance of non-muscle-invasive BC [1,2]
We undertook a pilot study to evaluate whether measuring common BC-associated mutations in urinary DNA can contribute to the monitoring of treatment responses in patients with organ-confined muscle-invasive BC (MIBC) treated with curative intent
As part of the TUXEDO trial, urine samples were collected from patients with MIBC before, during and after treatment with chemoradiotherapy
Summary
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer. Naheema S; Baxter, Laura A; Goel, Anshita; Arnold, Roland; Kaur, Baljit; Liu, Wenyu; Pirrie, Sarah J; Hussain, Syed; Viney, Richard; Ford, Daniel; Zarkar, Anjali; Wood, Mary A; Mitin, Timur; Thompson, Reid F; James, Nicholas D; Ward, Douglas G; Bryan, Richard T. Document Version Publisher's PDF, known as Version of record Citation for published version (Harvard): Gordon, NS, Baxter, LA, Goel, A, Arnold, R, Kaur, B, Liu, W, Pirrie, SJ, Hussain, S, Viney, R, Ford, D, Zarkar, A, Wood, MA, Mitin, T, Thompson, RF, James, ND, Ward, DG & Bryan, RT 2021, 'Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study', BJU International .
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
